PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Clinical trials for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) explained in plain language.
Never miss a new study
Get alerted when new PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) trials appear
Sign up with your email to follow new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo tested in fight against tough pancreatic cancer
Disease control Recruiting nowThis early-stage study is testing the safety and effectiveness of combining two drugs, HRS-4642 and nimotuzumab, for people with advanced pancreatic cancer that has returned or spread. It will involve about 20 patients to find the right dose and see if the treatment helps shrink …
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Apr 01, 2026 21:41 UTC
-
Radioactive glue injection offers new hope for tough pancreatic tumors
Disease control Recruiting nowThis study is testing a new, one-time treatment for pancreatic cancer that cannot be removed by surgery. Doctors inject a radioactive 'glue' directly into the tumor to deliver targeted radiation, while patients continue their standard chemotherapy. The main goals are to see if th…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: NA • Sponsor: BetaGlue Therapeutics SpA • Aim: Disease control
Last updated Apr 01, 2026 21:41 UTC
-
New hope for tough cancer: experimental drug joins fight against pancreatic tumors
Disease control Recruiting nowThis study is testing whether adding an experimental drug called pumitamig (BNT327) to standard chemotherapy helps people with newly diagnosed metastatic pancreatic cancer. It will involve about 105 adults who have not yet received treatment for their advanced cancer. The main go…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Personalized cell therapy trial offers new hope for Tough-to-Treat cancers
Disease control Recruiting nowThis study is testing a new type of cell therapy for people with advanced solid tumors that have stopped responding to standard treatments. Doctors will analyze a patient's tumor to select a specific target, then infuse specially engineered immune cells (CAR-NK cells) from a heal…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: Essen Biotech • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New drug trial opens for patients with advanced cancers
Disease control Recruiting nowThis is an early-stage study testing a new drug called MT-4561 in people with various advanced solid tumors who have run out of standard treatment options. The main goals are to find a safe dose, see how the body processes the drug, and check for any early signs that it might hel…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: Tanabe Pharma America, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New hope for pancreatic cancer patients in global drug trial
Disease control Recruiting nowThis study is testing whether a new drug called daraxonrasib, given alone or with standard chemotherapy, works better than chemotherapy alone for people with advanced pancreatic cancer that has spread. About 900 participants will be randomly assigned to receive one of three treat…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New oral pill targets common Cancer-Causing mutations in major trial
Disease control Recruiting nowThis study is testing a new oral medication called RMC-6236 in adults with advanced solid tumors, including lung, colorectal, and pancreatic cancers, that have specific RAS mutations. The main goals are to find a safe and effective dose and to see if the drug can help control the…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New oral drug targets 'undruggable' cancer mutations in major tumors
Disease control Recruiting nowThis study is testing an experimental oral medication called JYP0015 in adults with advanced cancers that have specific RAS mutations, including pancreatic, lung, and colorectal cancers. The trial aims to find a safe dose and see if the drug can shrink tumors in patients who have…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE2 • Sponsor: Guangzhou JOYO Pharma Co., Ltd • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New targeted therapy trial offers hope for Tough-to-Treat cancers
Disease control Recruiting nowThis study is testing an experimental drug called M9140 in people with advanced gastric, lung, or pancreatic cancer that has stopped responding to standard treatments. The trial aims to see if M9140 can shrink tumors and is safe for patients. It will enroll about 250 adults whose…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC
-
New immune cell therapy targets tough pancreatic cancer
Disease control Recruiting nowThis early-stage trial is testing a new type of treatment using specially engineered immune cells, called CAR-NK cells, for people with advanced pancreatic cancer that has spread or cannot be removed by surgery. The study aims to find a safe dose and see if the treatment can shri…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New weapon tested against tough cancers that have stopped responding
Disease control Recruiting nowThis is a first-in-human study to test the safety and early signs of effectiveness of a new drug called STRO-004 in adults with advanced solid tumors that have come back or stopped responding to other treatments. The trial will test STRO-004 alone and in combination with an exist…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New targeted drug trial offers hope for tough pancreatic cancer
Disease control Recruiting nowThis study is testing an experimental drug called BT5528 for adults with advanced pancreatic cancer that has spread and worsened after one prior treatment. The drug is designed to find and attack cancer cells by targeting a specific protein they often have. Researchers want to se…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE2 • Sponsor: BicycleTx Limited • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New drug combo tested for Tough-to-Treat pancreatic cancer
Disease control Recruiting nowThis study is testing a new drug called MR001, given alongside standard chemotherapy, for people with advanced pancreatic cancer that has gotten worse after their first treatment. The main goals are to find a safe dose of MR001 and to get an early look at whether the combination …
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Majory Biotechnology Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New drug trial targets 'Undruggable' cancer mutation
Disease control Recruiting nowThis early-stage study is testing a new drug called RMC-5127 in adults with advanced cancers that have a specific genetic change called KRAS G12V. The main goals are to find a safe dose and see how the body processes the drug, both when given alone and when combined with other ca…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New drug targets 'Undruggable' mutation in deadly pancreatic cancer
Disease control Recruiting nowThis study is testing an experimental drug called RNK08954 for people with advanced pancreatic cancer that has spread and has a specific genetic change called KRAS G12D. The main goals are to see if the drug is safe and if it can help slow or stop the cancer's growth. It is for a…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE2 • Sponsor: Ranok Therapeutics (Hangzhou) Co., Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New cancer drug trial offers hope for advanced solid tumors
Disease control Recruiting nowThis early-stage study is testing a new drug called BMS-986523, both alone and combined with other cancer treatments, in people with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to check if the drug is safe, how the body processes it,…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
First patients to receive new cancer drug targeting specific tumor mutations
Disease control Recruiting nowThis is the first study in people testing a new cancer drug called KO-2806. It aims to find a safe dose and see if the drug can help control advanced solid tumors, including certain lung, colorectal, pancreatic, and kidney cancers. The study will test the drug by itself and combi…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
Targeted radiation therapy tested for Tough-to-Treat cancers
Disease control Recruiting nowThis study is testing a two-part approach for people with advanced cancers that cannot be removed by surgery. First, a special imaging scan is used to see if a tumor has a specific target. If it does, a targeted radiation treatment is given to try to control the cancer. The main …
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: ITM Oncologics GmbH • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
Genetic clues may predict pancreatic cancer treatment success
Disease control Recruiting nowThis study is testing whether genetic analysis of pancreatic tumors can predict how well patients respond to chemotherapy before surgery. Researchers will give 45 patients with non-metastatic pancreatic cancer a standard chemotherapy combination called FOLFIRINOX, then analyze tu…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC
-
New Two-Pronged chemo attack on deadly pancreatic cancer
Disease control Recruiting nowThis early-stage trial is testing whether combining two chemotherapy approaches—one delivered directly into the abdomen and another into the bloodstream—is safe and effective for adults with pancreatic cancer that has spread to the abdominal lining. Researchers want to see if thi…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Mar 13, 2026 15:06 UTC
-
New drug combo tested in fight against tough pancreatic cancer
Disease control Recruiting nowThis early-stage trial is testing the safety and best dose of a new drug called ProAgio when given alongside standard chemotherapy for advanced pancreatic cancer. It will enroll about 46 adults who have not yet received treatment for their metastatic disease. The main goal is to …
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1 • Sponsor: ProDa BioTech, LLC • Aim: Disease control
Last updated Mar 02, 2026 15:28 UTC
-
One blood test for six cancers? new study aims to revolutionize early detection
Diagnosis Recruiting nowThis study aims to develop a simple blood test to detect six different gastrointestinal cancers earlier than current methods. Researchers will analyze blood samples from 1,000 people, including those with cancer and healthy controls, to find tiny genetic signals that indicate can…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Sponsor: City of Hope Medical Center • Aim: Diagnosis
Last updated Apr 01, 2026 14:43 UTC
-
New scan aims to sharpen the picture for pancreatic cancer patients
Diagnosis Recruiting nowThis study is testing a new type of imaging scan to see if it can more accurately detect when pancreatic cancer has spread to other parts of the body. It will involve about 200 adults with confirmed pancreatic cancer who are being evaluated for treatment. The goal is to see if th…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE3 • Sponsor: SOFIE • Aim: Diagnosis
Last updated Mar 27, 2026 12:39 UTC
-
New scan aims to spot deadly pancreatic cancer sooner
Diagnosis Recruiting nowThis study is testing a new type of PET scan called FAPI PET to see if it can detect the return or spread of pancreatic cancer earlier than current standard scans like CT or MRI. It involves 35 patients who have already been diagnosed with non-metastatic pancreatic cancer and are…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE2 • Sponsor: Institut Curie • Aim: Diagnosis
Last updated Mar 23, 2026 15:16 UTC